Allergan acquires Motus following positive diabetic gastroparesis trial
Results of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus’ ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes has led to Allergan exercising its option to acquire Motus Therapeutics.
